The double challenge of resistant hypertension and chronic kidney disease

The Lancet

Volumn 386, Issue 10003, 2015, Pages 1588-1598

  Rossignol, Patrick ^a,b,c   Massy, Ziad A ^d,e   Azizi, Michel ^f,g,h   Bakris, George ⁱ   Ritz, Eberhard ^j   Covic, Adrian ^k   Goldsmith, David ^l   Heine, Gunnar H ^m   Jager, Kitty J ⁿ   Kanbay, Mehmet ^o   Mallamaci, Francesca ^p   Ortiz, Alberto ^q,r,s,t   Vanholder, Raymond ^u   Wiecek, Andrzej ^v   Zoccali, Carmine ^p   London, Gérard Michel ^f   Stengel, Bénédicte ^e   Fouque, Denis ^w  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Association Lorraine Pour le Traitement de l'Insuffisance Ré Nale   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h INSERM   (France)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^l GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^m SAARLAND UNIVERSITY   (Germany)

ⁿ UNIVERSITY OF AMSTERDAM   (Netherlands)

^o KOÇ UNIVERSITY   (Turkey)

^p BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^q 28400 Madrid   (Spain)

^r UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^s Instituto Carlos IIIFEDER   (Spain)

^t Grupo de Estudios Peritoneales de Madrid de REDinREN   (Spain)

^u GHENT UNIVERSITY HOSPITAL   (Belgium)

^v MEDICAL UNIVERSITY OF SILESIA   (Poland)

^w CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CHLORTALIDONE; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGING; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERVOLEMIA; KIDNEY DENERVATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESISTANT HYPERTENSION; REVIEW; SODIUM DEPLETION; SODIUM INTAKE; SODIUM RESTRICTION; BLOOD PRESSURE; COMPLICATION; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIET, SODIUM-RESTRICTED; DIURETICS; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84947329649     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00418-3     Document Type: Review

References (97)

1. DA Calhoun, D Jones, S Textor et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 2008 1403 1419
2. PA Sarafidis, P Georgianos, GL Bakris Resistant hypertension - its identification and epidemiology Nat Rev Nephrol 9 2013 51 58
3. G Mancia, R Fagard, K Narkiewicz the Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 31 2013 1281 1357
4. A Levin, PE Stevens Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward Kidney Int 85 2014 49 61
5. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease Kidney Int Suppl 2 2012 337 414
6. K Dasgupta, RR Quinn, KB Zarnke et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension Can J Cardiol 30 2014 485 501
7. PA James, S Oparil, BL Carter et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
8. AV Chobanian, GL Bakris, HR Black the National Heart Lung Blood Institute Joint National Committee on Prevention Detection Evaluation Treatment of High Blood Pressure the National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
9. MA Weber, EL Schiffrin, WB White et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension J Hypertens 32 2014 3 15
10. National Institute for Health and Care Excellence Chronic kidney disease (partial update) http://www.nice.org.uk/guidance/cg182/evidence/cg182-chronic-kidney-disease-update-full-guideline3 2004 (accessed Oct 5, 2015).
11. National Institute for Health and Care Excellence Hypertension: clinical management of primary hypertension in adults http://www.nice.org.uk/guidance/cg127/resources/guidance-hypertension-pdf 2011 (accessed Oct 5, 2015).
12. National Institute for Health and Care Excellence Type 2 diabetes: the management of type 2 diabetes http://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf 2014 (accessed Oct 5, 2015).
13. National Heart Foundation of Australia Guide to management of hypertension 2008, 2010 update http://www.heartfoundation.org.au/SiteCollectionDocuments/HypertensionGuidelines2008to2010Update.pdf 2010 (accessed Oct 5, 2015).
14. SD Persell Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 2011 1076 1080
15. B Stengel, M Metzger, M Froissart et al. Epidemiology and prognostic significance of chronic kidney disease in the elderly - the Three-City prospective cohort study Nephrol Dial Transplant 26 2011 3286 3295
16. RM Tanner, DA Calhoun, EK Bell et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD Clin J Am Soc Nephrol 8 2013 1583 1590
17. C McAdam-Marx, X Ye, JC Sung, DI Brixner, KH Kahler Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting Clin Ther 31 2009 1116 1123
18. T Gijón-Conde, A Graciani, JR Banegas Resistant hypertension: demography and clinical characteristics in 6,292 patients in a primary health care setting Rev Esp Cardiol (Engl Ed) 67 2014 270 276
19. D Weitzman, G Chodick, V Shalev, C Grossman, E Grossman Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel Hypertension 64 2014 501 507
20. P Muntner, A Anderson, J Charleston the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study Am J Kidney Dis 55 2010 441 451
21. BM Egan, Y Zhao, J Li et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network Hypertension 62 2013 691 697
22. G Brambilla, M Bombelli, G Seravalle et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and eastern Europe: data from the BP-CARE study J Hypertens 31 2013 2018 2024
23. BK Mahmoodi, K Matsushita, M Woodward the Chronic Kidney Disease Prognosis Consortium Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis Lancet 380 2012 1649 1661
24. SL Daugherty, JD Powers, DJ Magid et al. Incidence and prognosis of resistant hypertension in hypertensive patients Circulation 125 2012 1635 1642
25. L De Nicola, FB Gabbai, R Agarwal et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients J Am Coll Cardiol 61 2013 2461 2467
26. GF Salles, CRL Cardoso, VS Pereira, R Fiszman, ES Muxfeldt Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study J Hypertens 29 2011 2014 2023
27. MR Irvin, JN Booth 3rd, D Shimbo et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality J Am Soc Hypertens 8 2014 405 413
28. P Muntner, BR Davis, WC Cushman the ALLHAT Collaborative Research Group Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertension 64 2014 1012 1021
29. RM Tanner, DA Calhoun, EK Bell et al. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study Am J Kidney Dis 63 2014 781 788
30. PA Kalra, H Guo, AT Kausz et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis Kidney Int 68 2005 293 301
31. JW Funder, RM Carey, C Fardella the Endocrine Society Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline J Clin Endocrinol Metab 93 2008 3266 3281
32. DA Niculescu, G Ismail, C Poiana Plasma free metanephrine and normetanephrine levels are increased in patients with chronic kidney disease Endocr Pract 20 2014 139 144
33. LK Nieman, BM Biller, JW Findling et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 93 2008 1526 1540
34. E Grossman, FH Messerli Drug-induced hypertension: an unappreciated cause of secondary hypertension Am J Med 125 2012 14 22
35. PA Sarafidis, GL Bakris Resistant hypertension: an overview of evaluation and treatment J Am Coll Cardiol 52 2008 1749 1757
36. J Vega, JD Bisognano The prevalence, incidence, prognosis, and associated conditions of resistant hypertension Semin Nephrol 34 2014 247 256
37. O Jung, JL Gechter, C Wunder et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis J Hypertens 31 2013 766 774
38. M Tomaszewski, C White, P Patel et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis Heart 100 2014 855 861
39. KE Schmitt, CF Edie, P Laflam, LA Simbartl, CV Thakar Adherence to antihypertensive agents and blood pressure control in chronic kidney disease Am J Nephrol 32 2010 541 548
40. M Burnier, M Pruijm, G Wuerzner, V Santschi Drug adherence in chronic kidney diseases and dialysis Nephrol Dial Transplant 30 2015 39 44
41. PA Sarafidis Epidemiology of resistant hypertension J Clin Hypertens 13 2011 523 528
42. JM Bugnicourt, O Godefroy, JM Chillon, G Choukroun, ZA Massy Cognitive disorders and dementia in CKD: the neglected kidney-brain axis J Am Soc Nephrol 24 2013 353 363
43. N Desai, V Madhavankutty Saraswathy, K Hunter, C McFadden Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic J Clin Hypertens 15 2013 375 379
44. SD Fraser, PJ Roderick, NJ McIntyre et al. Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care BMC Fam Pract 14 2013 88
45. M Briet, P Boutouyrie, S Laurent, GM London Arterial stiffness and pulse pressure in CKD and ESRD Kidney Int 82 2012 388 400
46. CA Peralta, KC Norris, S Li the KEEP Investigators Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP) Arch Intern Med 172 2012 41 47
47. LJ Chesterton, MK Sigrist, T Bennett, MW Taal, CW McIntyre Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness Nephrol Dial Transplant 20 2005 1140 1147
48. P Studinger, Z Lénárd, B Mersich, GS Reusz, M Kollai Determinants of baroreflex function in juvenile end-stage renal disease Kidney Int 69 2006 2236 2242
49. FU Mattace-Raso, AH van den Meiracker, WJ Bos et al. Arterial stiffness, cardiovagal baroreflex sensitivity and postural blood pressure changes in older adults: the Rotterdam Study J Hypertens 25 2007 1421 1426
50. Y Okada, MM Galbreath, S Shibata et al. Relationship between sympathetic baroreflex sensitivity and arterial stiffness in elderly men and women Hypertension 59 2012 98 104
51. SC Hung, KL Kuo, CH Peng et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease Kidney Int 85 2014 703 709
52. E Pimenta, KK Gaddam, S Oparil et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial Hypertension 54 2009 475 481
53. FP Cappuccio Salt and cardiovascular disease BMJ 334 2007 859 860
54. AJ Kwakernaak, JA Krikken, SH Binnenmars et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial Lancet Diabetes Endocrinol 2 2014 385 395
55. JE Heeg, PE de Jong, GK van der Hem, D de Zeeuw Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril Kidney Int 36 1989 272 279
56. L Vogt, F Waanders, F Boomsma, D de Zeeuw, G Navis Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan J Am Soc Nephrol 19 2008 999 1007
57. T Krause, K Lovibond, M Caulfield, T McCormack, B Williams the Guideline Development Group Management of hypertension: summary of NICE guidance BMJ 343 2011 d4891
58. JP Garg, WJ Elliott, A Folker, M Izhar, HR Black the RUSH University Hypertension Service Resistant hypertension revisited: a comparison of two university-based cohorts Am J Hypertens 18 2005 619 626
59. EJ McMahon, JD Bauer, CM Hawley et al. A randomized trial of dietary sodium restriction in CKD J Am Soc Nephrol 24 2013 2096 2103
60. Kidney Disease Outcomes Quality Initiative (KDOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 suppl 1 2004 S1 290
61. V Bellizzi, BR Di Iorio, L De Nicola the ERIKA Study-group Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease Kidney Int 71 2007 245 251
62. S Subramanian, BW Teo, QC Toh et al. Spot urine tests in predicting 24-hour urine sodium excretion in Asian patients J Ren Nutr 23 2013 450 455
63. J Titze A different view on sodium balance Curr Opin Nephrol Hypertens 24 2015 14 20
64. A Dahlmann, K Dörfelt, F Eicher et al. Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients Kidney Int 87 2015 434 441
65. J Tamargo, J Segura, LM Ruilope Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents Expert Opin Pharmacother 15 2014 605 621
66. J Tamargo, J Segura, LM Ruilope Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics Expert Opin Pharmacother 15 2014 527 547
67. B Dussol, J Moussi-Frances, S Morange, C Somma-Delpero, O Mundler, Y Berland A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease J Clin Hypertens 14 2012 32 37
68. SS Shankar, DC Brater Loop diuretics: from the Na-K-2Cl transporter to clinical use Am J Physiol Renal Physiol 284 2003 F11 F21
69. R Agarwal, AD Sinha, MK Pappas, F Ammous Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study Am J Nephrol 39 2014 171 182
70. G Bobrie, M Frank, M Azizi et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study J Hypertens 30 2012 1656 1664
71. F Verbeke, E Lindley, L Van Bortel et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application Nephrol Dial Transplant 29 2014 490 496
72. HH Parving, BM Brenner, JJ McMurray the ALTITUDE Investigators Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 2012 2204 2213
73. LF Fried, N Emanuele, JH Zhang the VA NEPHRON-D Investigators Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 2013 1892 1903
74. P Susantitaphong, K Sewaralthahab, EM Balk, S Eiam-ong, NE Madias, BL Jaber Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis Am J Hypertens 26 2013 424 441
75. SC Palmer, D Mavridis, E Navarese et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis Lancet 385 2015 2047 2056
76. M Azizi, L Perdrix, G Bobrie et al. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension J Hypertens 32 2014 2038 2044
77. G Liu, XX Zheng, YL Xu, J Lu, RT Hui, XH Huang Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis J Hum Hypertens 29 2015 159 166
78. D Bolignano, SC Palmer, SD Navaneethan, GF Strippoli Aldosterone antagonists for preventing the progression of chronic kidney disease Cochrane Database Syst Rev 4 2014 CD007004
79. B Williams, TM MacDonald, S Morant et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial Lancet 2015 published online Sept 20, 2015. http://dx.doi.org/10.1016/S0140-6736(15)00257-3
80. H Krum, MP Schlaich, PA Sobotka et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study Lancet 383 2014 622 629
81. MD Esler, H Krum, M Schlaich, RE Schmieder, M Böhm, PA Sobotka the Symplicity HTN-2 Investigators Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial Circulation 126 2012 2976 2982
82. DL Bhatt, DE Kandzari, WW O'Neill the SYMPLICITY HTN-3 Investigators A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 2014 1393 1401
83. GL Bakris, RR Townsend, JM Flack the SYMPLICITY HTN-3 Investigators 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial J Am Coll Cardiol 65 2015 1314 1321
84. EE Vink, R Goldschmeding, A Vink, C Weggemans, RL Bleijs, PJ Blankestijn Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study Nephrol Dial Transplant 29 2014 1608 1610
85. M Azizi, M Sapoval, P Gosse the Renal Denervation for Hypertension (DENERHTN) investigators Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial Lancet 385 2015 1957 1965
86. S Desch, T Okon, D Heinemann et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension Hypertension 65 2015 1202 1208
87. D Hering, F Mahfoud, AS Walton et al. Renal denervation in moderate to severe CKD J Am Soc Nephrol 23 2012 1250 1257
88. C Ott, F Mahfoud, A Schmid et al. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension J Hypertens 33 2015 1261 1266
89. F Zannad, WG Stough, F Mahfoud et al. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure Hypertension 65 2015 5 15
90. JD Bisognano, G Bakris, MK Nadim et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial J Am Coll Cardiol 58 2011 765 773
91. JD Bisognano, CL Kaufman, DS Bach, EG Lovett, P de Leeuw the DEBuT-HT and Rheos Feasibility Trial Investigators Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system J Am Coll Cardiol 57 2011 1787 1788
92. M Wallbach, LY Lehnig, C Schroer et al. Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension J Hypertens 33 2015 181 186
93. M Wallbach, LY Lehnig, C Schroer et al. Impact of baroreflex activation therapy on renal function - a pilot study Am J Nephrol 40 2014 371 380
94. K Wheatley, N Ives, R Gray the ASTRAL Investigators Revascularization versus medical therapy for renal-artery stenosis N Engl J Med 361 2009 1953 1962
95. CJ Cooper, TP Murphy, DE Cutlip the CORAL Investigators Stenting and medical therapy for atherosclerotic renal-artery stenosis N Engl J Med 370 2014 13 22
96. L Bax, AJ Woittiez, HJ Kouwenberg et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial Ann Intern Med 150 2009 840 848
97. J Ritchie, HV Alderson, PA Kalra Where now in the management of renal artery stenosis? Implications of the ASTRAL and CORAL trials Curr Opin Nephrol Hypertens 23 2014 525 532